Economic Benefits of BIS-Aided Assessment of post-BC Lymphedema in the United States.
Economic analysis demonstrating that BIS utilization would lead to a cost savings which is magnified when considering sequelae of BCRL.
Over 1 year, BIS-aided assessment of lymphedema for patients following treatment for BC results in cost savings, even without considering potential cost savings associated with averted downstream sequelae.
Bilir, S.P., M.P. DeKoven, and J. Munakata, Economic benefits of BIS-aided assessment of post-BC lymphedema in the United States. Am J Manag Care, 2012. 18(5): p. 234-41.